Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2017 Dec 19;4(1):55-57.
doi: 10.1016/j.jdcr.2017.06.035. eCollection 2018 Jan.

Ibrutinib-associated pityriasis rosea-like rash

Carole Bitar  1 , Azeen Sadeghian  1 , Lacey Sullivan  2 , Andrea Murina  1
Affiliations
Case Reports

Ibrutinib-associated pityriasis rosea-like rash

Carole Bitar et al. JAAD Case Rep. .
No abstract available

Keywords: CLL, chronic lymphocytic leukemia; EGFR, epidermal growth factor receptor; PDGFR, platelet-derived growth factor receptor; PR, pityriasis rosea; drug reaction; ibrutinib; pityriasis rosea.

PubMed Disclaimer

Figures

Fig 1
Fig 1
Clinical images of the rash over the right flank and right axilla. A, A 3-cm violaceous plaque with an inward-facing central scale on the right flank. B, Multiple grouped violaceous scaly papules each measuring 0.5 to 1 cm under the right axilla.
Fig 2
Fig 2
Histopathologic images of punch biopsy specimens obtained from the right flank. A, Superficial perivascular infiltrate with spongiosis. B, Perivascular cell infiltrates consisting of lymphocytes and eosinophils, suggestive of drug eruption. (Hematoxylin–eosin stain; original magnification: A, ×4; B, ×10.)
See this image and copyright information in PMC

References

    1. Saba N., Ghias M., Manepalli R. Auranofin induces a reversible in-vivo stress response that correlates with a transient clinical effect in patients with chronic lymphocytic leukemia. Blood. 2013;122:3819.
    1. Farooqui M.Z., Valdez J., Martyr S. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. Lancet Oncol. 2015;16:169–176. - PMC - PubMed
    1. Bitar C., Farooqui M.Z., Valdez J. Hair and nail changes during long-term therapy with ibrutinib for chronic lymphocytic leukemia. JAMA Dermatol. 2016;152:698–701. - PMC - PubMed
    1. Iberri D.J., Kwong B.Y., Stevens L.A. Ibrutinib-associated rash: a single-centre experience of clinicopathological features and management. Br J Haematol. 2016 [Epub ahead of print] - PubMed
    1. Mannis G., Wu D., Dea T., Mauro T., Hsu G. Ibrutinib rash in a patient with 17p del chronic lymphocytic leukemia. Am J Hematol. 2015;90:179. - PMC - PubMed

Publication types